Single ascending dose study of SAR439459 in adults with osteogenesis imperfecta (OI)

Trial Identifier: SAD17378
Sponsor: Sanofi
Start Date: August 2022
Primary Completion Date: November 2024
Study Completion Date: November 2024
Condition: Osteogenesis Imperfecta

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Australia, New South Wales Westmead, New South Wales, Australia, 2145
Australia, Victoria Clayton, Victoria, Australia, 3168
Canada Toronto, Canada, M5G 2C4
Canada, Ontario Oakville, Ontario, Canada, L6M 1M1
France Lyon, France, 69003
France Paris, France, 75010
United States, California Los Angeles, California, United States, 90095
United States, Connecticut New Haven, Connecticut, United States, 06510
United States, Indiana Indianapolis, Indiana, United States, 46202
United States, Maryland Baltimore, Maryland, United States, 21205
United States, Texas Houston, Texas, United States, 77030
UNITED STATES, Ohio Cincinnati, Ohio, UNITED STATES, 45229
UNITED STATES, Tennessee Nashville, Tennessee, UNITED STATES, 37232